source
- Degron Therapeutics raises $40M in Series A extension, total $95M, as Cabaletta releases early CAR‑T dataDegron Therapeutics, a US‑China biotech focused on molecular‑glue degrader technology, announced an additional $40 million in Series A extension funding, bringing its total capital raised to $95 mi…
- Biogen's anti-tau Alzheimer drug BIIB080 fails primary endpoint in Phase 2, but shows slower declineBiogen reported results of its Phase 2 trial of BIIB080, a tau-targeting therapy for Alzheimer’s disease. The study’s primary endpoint was not met, meaning the drug did not achieve the pre-specifi…